Introduction {#section5-1534735420943280}
============

Traditional Chinese medicine (TCM) has been practiced for thousands of years to treat musculoskeletal problems, respiratory diseases, neurological disorders, and gastrointestinal discomfort.^[@bibr1-1534735420943280][@bibr2-1534735420943280][@bibr3-1534735420943280][@bibr4-1534735420943280]-[@bibr5-1534735420943280]^ TCM is the mainstay of complementary and alternative medicine therapies and includes Chinese herbal medicine (CHM), acupuncture, and manipulative treatment. In Taiwan, patients use Chinese herbal extractions to treat diseases according to the theory of CHM. In recent years, more and more Taiwanese patients have tried CHM for complementary interventions following a cancer diagnosis, including hematologic malignant diseases.^[@bibr6-1534735420943280],[@bibr7-1534735420943280]^

Multiple myeloma (MM) is a hematologic malignant disease that arises from the abnormal proliferation of plasma cells.^[@bibr8-1534735420943280]^ Males and elderly individuals are more predisposed to MM.^[@bibr9-1534735420943280]^ Bone pain is one of clinical characteristics of MM; nevertheless, clinical doctors still find it difficult to confirm the diagnosis until other specific symptoms can be noted, such as renal failure and hypercalcemia.^[@bibr10-1534735420943280]^ Although duration of survival has been lengthened after chemotherapy, both clinicians and patients are unsatisfied with current treatment results because high-dose chemotherapy is hard to prescribe to elderly patients.^[@bibr11-1534735420943280]^ Furthermore, hematopoietic stem cell transplantation (HSCT) is another powerful intervention for MM patients.^[@bibr12-1534735420943280]^ However, it remains unsuitable for elderly patients.^[@bibr13-1534735420943280]^ The 5-year survival rate of MM is approximately 15% in populations that respond well to chemotherapy, and those who undergo HSCT could add to their lives.^[@bibr14-1534735420943280]^ MM patients seek to overcome the complications from standard therapy and to arrive at better treatment outcomes with complementary therapies. In Taiwan, even hematological doctors in medical centers recommended that their MM patients partake CHM as a complementary intervention.^[@bibr6-1534735420943280]^ Thus, we sought to use the National Health Insurance Research Database (NHIRD) to investigate whether MM patients could benefit from CHM for MM.

The National Health Insurance (NHI) program was enacted by the National Health Insurance Administration in Taiwan in 1995. Currently, the overall NHI coverage in Taiwan is over 99.6%. Information from the Taiwanese NHIRD, therefore, represents almost the entire Taiwanese population. The NHIRD is a large-scale long-term follow-up database for medical interventions often used to avoid sampling biases.^[@bibr15-1534735420943280]^ TCM services have also been reimbursed by the NHI program since 1996.^[@bibr16-1534735420943280]^

However, evidence supporting the idea that CHM is helpful for improving the survival rate in MM patients is limited. In addition, there is no large-scale clinical trial based on large populations of MM patients. Thus, we sought to use the NHIRD to investigate whether MM patients could benefit from CHM.

Methods {#section6-1534735420943280}
=======

Data Sources {#section7-1534735420943280}
------------

The Registry for Catastrophic Illness Patients, which records all original claims data, such as clinical visits, demographic characteristics, hospitalizations, diagnosis, medical costs, interventions, and prescriptions, was used as our data source.^[@bibr17-1534735420943280]^ TCM services such as CHM, manipulative therapies, and acupuncture were all covered by the NHI. Diagnosis was coded by the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).

Study Cohort Identification {#section8-1534735420943280}
---------------------------

We identified patients who were newly diagnosed with MM from January 1, 2002, to December 31, 2012, and followed them until the end of 2013 ([Figure 1](#fig1-1534735420943280){ref-type="fig"}). Patients with at least 2 ambulatory or inpatient claims with a diagnosis of ICD-9-CM code 203.00 were included. We excluded patients aged younger than 18 years, those with incomplete data on age or sex, those with interrupted health insurance services during the follow-up period, and those with a follow-up time \<1 month. Participants who accepted CHM therapy lasting ≥1 month and from the initial diagnosis of MM to December 31, 2012, were enrolled in the CHM cohort. A propensity score approach was used to minimize confounding factors by the indication of CHM treatment and the caliper value was 0.2. Through multiple logistic regression analysis, a 1:1 propensity score match was performed by age, sex, urbanization level, comorbidities, and standard Western treatment program. No significant difference was found in age, sex, urbanization level, comorbidities, and standard Western treatment program compared with the general population after propensity score matching. Index date was defined as the first date of MM diagnosis. Immortal time was defined as the period from the initial diagnosis of MM to the date of death or end date of study. The most common single herb and herbal formulas prescribed to patients with MM were analyzed. These prescriptions are presented by their phonetic transcriptions and Latin names. Ratios of the ingredients of multiherb products were also included.

![Study population flowchart. A total of 1,988 patients with MM were newly diagnosed from 2002 to 2012. After 1:1 propensity score matching by sex, age, and index date, 156 patients were included in the CHM cohort and non-CHM cohorts, respectively. Abbreviations: MM, multiple myeloma; CHM, Chinese herbal medicine.](10.1177_1534735420943280-fig1){#fig1-1534735420943280}

Covariate Assessment {#section9-1534735420943280}
--------------------

Age and sex are sociodemographic factors, and we divided patients into 3 groups according to age (18-49 years, 50-64 years, and ≥65 years). ICD-9-CM codes of comorbidities identified more than one time in the outpatient or inpatient records before the primary diagnosis of MM were taken into consideration, and presented as the Charlson Comorbidity Index (CCI).

Ethical Considerations {#section10-1534735420943280}
----------------------

There was no informed consent requirement because the secondary data for research was included in the NHIRD. Database users could not identify individuals or caregivers directly. The Research Ethics Committee of Taichung Tzu Chi Hospital approved this study (REC103-43).

Statistical Analyses {#section11-1534735420943280}
--------------------

Baseline characteristics are presented as the means (standard deviations) or n (%), and the differences between the CHM and non-CHM cohorts were compared using paired *t* tests and χ^2^ tests for numeric and categorical variables, respectively. Cox proportional hazards regression was used to estimate crude and adjusted hazard ratios (HRs) of CHM therapy. The difference in the risk of death between the CHM and non-CHM cohorts was estimated using the Kaplan-Meier method with the log-rank test. All data analysis was performed by using commercial statistical software SPSS version 22 (IBM Corp, Released 2013) and SAS 9.3 (SAS Institute). We defined *P* \< .05 in 2-tailed tests as statistically significant.

Results {#section12-1534735420943280}
=======

A total of 1,640 patients were newly diagnosed with MM with at least 2 clinical visits recorded in the NHIRD from January 1, 2002, to December 31, 2012 ([Figure 1](#fig1-1534735420943280){ref-type="fig"}). We excluded patients aged younger than 18 years, without detailed information, who died before the index date, or who had partaken of a CHM treatment for \<30 days. The number of included patients was 1,555; then, we performed 1:1 propensity score matching by age, sex, urbanization level, CCI, and standard anticancer interventions to compare the 2 groups. In the final cohort, 156 patients were included in the non-CHM and CHM cohorts, respectively.

[Table 1](#table1-1534735420943280){ref-type="table"} shows the baseline characteristics of both cohorts, with similar distributions of age, sex, urbanization level, CCI, bortezomib usage, and HSCT. Male participants were predominant in both cohorts, and the percentages of each age group were the same (54.5%). Most patients came from the lowest urbanization level (\>90%) and had a 0 for the CCI (\>46%). Bortezomib was used by approximately 44% of patients. Most patients had not undergone HSCT (\>98%).

###### 

Characteristics of MM Patients According to Use of CHM.

![](10.1177_1534735420943280-table1)

  Variable                                                                        Patients of MM   *P*                           
  ------------------------------------------------------------------------------- ---------------- ------------- -------- ------ -------
  Gender^[a](#table-fn2-1534735420943280){ref-type="table-fn"}^                                                                  
   Female                                                                         71               45.5          71       45.5   1.000
   Male                                                                           85               54.5          85       54.5   
  Age group^[b](#table-fn3-1534735420943280){ref-type="table-fn"}^ (years)                                                       
   18-49                                                                          22               14.1          19       12.2   .846
   50-64                                                                          73               46.8          77       49.4   
   ≥65                                                                            61               39.1          60       38.5   
   Age mean^[c](#table-fn4-1534735420943280){ref-type="table-fn"}^ ± SD (years)   62.9 ± 10.5      62.4 ± 10.6   .724            
  Urbanization level^[b](#table-fn3-1534735420943280){ref-type="table-fn"}^                                                      
   1 (highest)                                                                    7                4.5           1        0.6    .054
   2                                                                              4                2.6           8        5.1    
   3 (lowest)                                                                     145              92.9          147      94.2   
  CCI score^[a](#table-fn2-1534735420943280){ref-type="table-fn"}^                                                               
   0                                                                              73               46.8          75       48.1   .847
   1                                                                              51               32.7          53       34.0   
   ≥2                                                                             32               20.5          28       17.9   
  Bortezomib^[a](#table-fn2-1534735420943280){ref-type="table-fn"}^               62               39.7          77       49.4   .088
  HSCT^[a](#table-fn2-1534735420943280){ref-type="table-fn"}^                                                                    
   No                                                                             153              98.1          153      98.1   1.000
   Yes                                                                            3                1.9           3        1.9    
  Follow-up time (mean, median)                                                   1.76 (1.46)      3.01 (2.75)   \<.001          

Abbreviations: MM, multiple myeloma; CHM, Chinese herbal medicine; CCI, Charlson Comorbidity Index; HSCT, hematopoietic stem cell transplantation.

χ^2^ test.

Fischer's exact test.

*t* test.

[Table 2](#table2-1534735420943280){ref-type="table"} presents the related HR of the mortality through a Cox proportional hazards model. After adjusting for age, sex, urbanization level, CCI, and treatment received, the adjusted HR of morbidity in the CHM group was 0.29 (95% confidence interval \[CI\] = 0.20-0.41; *P* \< .0001), which was significantly different from that of the non-CHM group. Lag time to treatment was defined as the time of diagnosis to the time of the initiation of CHM treatment. Its influence on the improvement of prognosis has not yet been reported because the lag time to treatment may vary.^[@bibr18-1534735420943280],[@bibr19-1534735420943280]^ After including lag time in the analysis, we obtained an adjusted HR of 0.35 (95% CI = 0.24-0.51, *P* \< .0001).

###### 

Cox Model With HRs and 95% CIs of Mortality Associated With CHM and Covariates Among MM Patients.

![](10.1177_1534735420943280-table2)

  Variable   Patients of MM                                                                                
  ---------- ---------------- ------ ----------- --------- ------ ----------- --------- ------ ----------- ---------
  CHM use                                                                                                  
   Non-CHM   96               1.00   Reference             1.00   Reference             1.00   Reference   
   CHM       49               0.29   0.21-0.42   \<.0001   0.29   0.20-0.41   \<.0001   0.35   0.24-0.51   \<.0001

Abbreviations: HR, hazard ratio; CI, confidence interval; CHM, Chinese herbal medicine; MM, multiple myeloma; CCI, Charlson Comorbidity Index.

Relative HR.

Represented adjusted HR: mutually adjusted for CHM use, age, gender, urbanization level, and CCI score in Cox proportional hazard regression.

Adjusted for CHM use, age, gender, urbanization level, CCI score, and treatment as well as the lag time for each patient, which was defined as the time from MM diagnosis to initial CHM treatment.

[Table 3](#table3-1534735420943280){ref-type="table"} reveals the cumulative days of CHM use among MM patients through the Cox proportional hazards model. Comparing with patients from the non-CHM group, patients who used CHM for 30 to 59 days had an adjusted HR of 0.35 (95% CI = 0.21-0.58, *P* \< .001); those who used CHM for 60 to 179 days had an adjusted HR of 0.29 (95% CI = 0.17-0.49, *P* \< .001); and those who used CHM for ≥180 days had an adjusted HR of 0.23 (95% CI = 0.13-0.41, *P* \< .001). The median lag time from the diagnosis of MM to CHM treatment was 100 days in the subgroup of patients with 30 to 59 days of CHM treatment; 173 days in the subgroup with 60 to 179 days of CHM treatment; and 34 days in the subgroup with ≥180 days of CHM treatment.

###### 

HRs and 95% CIs of Mortality Risk Associated With Cumulative Use Day of CHM Among MM Patients.

![](10.1177_1534735420943280-table3)

                                      N     Frequency of death (N = 156)   Median lag time to CHM treatment (day)   HR (95% CI)                                                                   
  ----------------------------------- ----- ------------------------------ ---------------------------------------- ----------------------------------------------------------------------------- -----------------------------------------------------------------------------
  Non-CHM user (included \<30 days)   156   96                             ---                                      1 (reference)                                                                 1 (reference)
  CHM user                                                                                                                                                                                        
   30-59 days                         47    20                             100                                      0.38 (0.23-0.63)[\*\*\*](#table-fn12-1534735420943280){ref-type="table-fn"}   0.35 (0.21-0.58)[\*\*\*](#table-fn12-1534735420943280){ref-type="table-fn"}
   60-179 days                        57    16                             173                                      0.30 (0.18-0.51)[\*\*\*](#table-fn12-1534735420943280){ref-type="table-fn"}   0.29 (0.17-0.49)[\*\*\*](#table-fn12-1534735420943280){ref-type="table-fn"}
   ≥180 days                          52    13                             34                                       0.22 (0.12-0.39)[\*\*\*](#table-fn12-1534735420943280){ref-type="table-fn"}   0.23 (0.13-0.41)[\*\*\*](#table-fn12-1534735420943280){ref-type="table-fn"}

Abbreviations: HR, hazard ratio; CI, confidence interval; CHM, Chinese herbal medicine; MM, multiple myeloma; CCI, Charlson Comorbidity Index.

Relative HR.

Represented adjusted HR: mutually adjusted for CHM use, age, gender, urbanization level, CCI score, and treatment in Cox proportional hazard regression.

*P* \< .05. \*\**P* \< .01. \*\*\**P* \< .001.

Compared with non-CHM group, the CHM group demonstrated better cumulative survival according to the Kaplan-Meier plots in [Figure 2](#fig2-1534735420943280){ref-type="fig"} (*P* \< .0001). [Figure 3](#fig3-1534735420943280){ref-type="fig"} also shows that compared with the non-CHM group, MM patients with CHM had higher cumulative survival, stratified by treatment duration (*P* \< .0001). [Figure 4](#fig4-1534735420943280){ref-type="fig"} reveals that compared with non-CHM patients, the CHM group had had better cumulative survival status after age stratification (*P* \< .0001).

![Kaplan-Meier curves of overall survival of MM patients according to treatment duration of CHM (green line) and non-CHM user (blue line). Patients in the CHM cohort had a higher cumulative survival rate (log-rank test, *P* \< .0001). Abbreviations: MM, multiple myeloma; CHM, Chinese herbal medicine.](10.1177_1534735420943280-fig2){#fig2-1534735420943280}

![Kaplan-Meier curves of overall survival in MM patients according to CHM use, stratified by treatment duration. Highest cumulative survival rate could be noted in treatment duration ≥180 days (log-rank test, *P* \< .0001). Abbreviations: MM, multiple myeloma; CHM, Chinese herbal medicine.](10.1177_1534735420943280-fig3){#fig3-1534735420943280}

![Kaplan-Meier curves of overall survival in MM patients according to CHM use, stratified by age (log-rank test, *P* \< .0001). Abbreviations: MM, multiple myeloma; CHM, Chinese herbal medicine.](10.1177_1534735420943280-fig4){#fig4-1534735420943280}

[Table 4](#table4-1534735420943280){ref-type="table"} reveals the Chinese herbal formulas and single herbs most commonly prescribed to patients with MM. The 3 most frequently prescribed Chinese herbal formulas and single herbs were Shu-Jing-Huo-Xue-Tang, Ban-Xia-Xie-Xin-Tang and Du-Huo-Ji-Sheng-Tang, and Tian-Hua-Fen (*Trichosanthes kirilowii* Maxim.), Da-Huang (*Rheum officinale* Baill.) and E-Zhu (*Curcuma kwangsiensis* S.G.Lee & C.F.Liang), respectively. The analyses of most of these prescriptions resulted in a *P* value \< .001.

###### 

HRs and 95% CIs of Mortality Risk Associated With the Most-Used Herbal Products Among MM Patients.

![](10.1177_1534735420943280-table4)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CHM type                            Ingredients and ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Accumulated person-days   n     Frequency of mortality   HR (95% CI)                                                                   
  ----------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- ----- ------------------------ ----------------------------------------------------------------------------- -----------------------------------------------------------------------------
  Non-Chinese herbal medicine group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   156                       96    1 (reference)            1 (reference)                                                                 

  Single-herb products                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

   Tian-Hua-Fen                       *Trichosanthes kirilowii* Maxim.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                8,703                     105   32                       0.29 (0.19-0.43)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}   0.29 (0.20-0.44)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}

   Da-Huang                           *Rheum officinale* Baill.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       2,748                     42    13                       0.33 (0.18-0.58)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}   0.35 (0.19-0.62)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}

   E-Zhu                              *Curcuma kwangsiensis* S.G.Lee & C.F.Liang                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      2,424                     10    5                        0.43 (0.17-1.06)                                                              0.51 (0.21-1.28)

   Ji-Xue-Teng                        *Spatholobus suberectus* Dunn                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   2,294                     29    7                        0.21 (0.10-0.46)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}   0.19 (0.09-0.42)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}

   Dan-Shan                           *Salvia miltiorrhiza* Bunge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     1,695                     33    7                        0.17 (0.08-0.38)[\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}     0.17 (0.08-0.37)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}

   Du-Zhong                           *Eucommia ulmoides* Oliv.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       1,556                     31    10                       0.30 (0.16-0.58)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}   0.32 (0.16-0.61)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}

   Pu-Gong-Ying                       *Taraxacum mongolicum* Hand.-Mazz.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1,466                     24    9                        0.36 (0.18-0.72)[\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}     0.34 (0.17-0.68)[\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}

   Yan-Hu-Suo                         *Corydalis yanhusuo* (Y.H.Chou & Chun C.Hsu) W.T.Wang ex Z.Y.Su & C.Y.Wu                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        1,377                     33    6                        0.16 (0.07-0.36)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}   0.18 (0.08-0.41)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}

   Niu-Xi                             *Achyranthes bidentata* Blume                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1,327                     29    5                        0.15 (0.06-0.36)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}   0.14 (0.06-0.35)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}

   Jie-Geng                           *Platycodon grandifloras* (Jacq.) A.DC.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         1,162                     41    13                       0.26 (0.15-0.48)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}   0.29 (0.16-0.53)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}

  Multiherb products                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

   Shu-Jing-Huo-Xue-Tan               Zhi-Gan-Cao (*Glycyrrhiza glabra* L.), Dang-Gui (*Angelica sinensis* (Oliv.) Diels), Bai-Shao (*Paeonia sterniana* H.R.Fletcher), Sheng-Di-Huang (*Rehmannia glutinosa* Libosch.), Cang-Zhu (*Atractylodes lancea* (Thunb.) DC.), Niu-Xi (*Achyranthes bidentata* Blume), Chen-Pi (*Citrus reticulata* Blanco), Tao-Ren (*Prunus persica* (L.) Batsch), Wei-Ling-Xian (*Clematis chinensis* Osbeck), Chuan-Xiong (*Ligusticum chuanxiong* Hort.), Fan-Gji (*Stephania tetrandra* S. Moore), Qiang-Huo (*Notopterygium incisum* Ting ex H. T. Chang), Fang-Feng (*Saposhnikovia divaricata* (Turcz.) Schischk), Bai-Zhi (*Angelica dahurica* (Fisch. ex Hoffm.) Benth. et Hook. f. var. *formosana* (Boiss.) Shan et Yuan), Long-Dan (*Gentiana manshurica* Kitag), Fu-Ling (*Poria cocos* (Schw.) Wolff), Shen-Gjiang (*Zingiber officinale* (Willd.) Rosc.)\   2,231                     36    11                       0.28 (0.14-0.53)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}   0.29 (0.15-0.56)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}
                                      1:2:2.5:2:2:2:2:2:2:1:1:1:1:1:1:1:3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

   Ban-Xia-Xie-Xin-Tang               Ban-Xia (*Pinellia ternata* (Thunb.) Makino); Huang-Qin (*Scutellaria baicalensis* Georgi), Gan-Jiang (*Zingiber officinale* Roscoe), Ren-Shen (*Panax ginseng* C.A.Mey.), Huang-Lian (*Coptis chinensis* Franch.), Da-Zao (*Ziziphus jujuba* Mill.), Zhi-Gan-Cao (*Glycyrrhiza glabra* L.)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    2,181                     33    5                        0.14 (0.06-0.33)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}   0.14 (0.06-0.34)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}
                                      7.5:4.5:4.5:4.5:1.5:3:4.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

   Du-Huo-Ji-Sheng-Tang               Du-Huo (*Angelica pubescens* Maxim.), Ji-Sheng (*Taxillus chinensis* (DC.) Danser), Du-Zhong (*Eucommia ulmoides* Oliv.), Niu-Xi (*Achyranthes bidentata* Blume), Xi-Xin (*Asarum heterotropoides* f. *mandshuricum* (Maxim.) Kitag.), *Qin-Jiao* (*Gentiana macrophylla* Pall.*)*, Fu-Ling (*Poria cocos* (Schw.) Wolff), Rou-Gui (*Cinnamomun cassia* Presl), Fang-Feng (*Saposhnikovia divaricata* (Turcz.) Schischk), Chuan-Qiong (*Ligusticum chuanxiong* Hortorum), Ren-Shan (*Panax ginseng* C.A.Mey.), Zhi-Gan-Cao (*Glycyrrhiza glabra* L.), Dang-Gui (*Angelica sinensis* (Oliv.) Diels), Bai-Shao (*Paeonia sterniana* H.R.Fletcher), Shou-Di-Huang (*Rehmannia glutinosa* Libosch.)\                                                                                                                                                                1,764                     31    8                        0.24 (0.11-0.49)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}   0.23 (0.11-0.47)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}
                                      3:2:2:2:2:2:2:2:2:2:2:2:2:2:2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

   Xiao-Chai-Hu-Tang                  Chai-Hu (*Bupleurum chinense* DC.), Huang-Qin (*Scutellaria baicalensis* Georgi), Ren-Shan (*Panax ginseng* C.A.Mey.), Ban-Xia (*Pinellia Ternate* (Thunb.) Makino), Zhi-Gan-Cao (*Glycyrrhiza glabra* L.), Sheng-Jiang (*Zingiber officinale* Roscoe), Da-Zao (*Ziziphus jujuba* Mill.)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       1,595                     28    9                        0.35 (0.18-0.70)[\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}     0.33 (0.17-0.66)[\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}
                                      8:3:3:3:5:3:2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

   Gan-Lu-Yin                         Shou-Di-Huang (*Rehmannia glutinosa* Libosch.), Mai-Men-Dong (*Ophiopogon japonicus* (Thunb.) Ker Gawl.), Zhi-Ke (*Citrus* × *aurantium* L.), Chi-Shao (red *Paeonia lactiflora* Pall.), Zhi-Gan-Cao (*Glycyrrhiza glabra* L.), Yin-Chen-Hao (*Artemisia capillaris* Thunb.), Pi-Pa-Ye (*Eriobotrya japonica* (Thunb.) Lindl.), Shi-Hu (*Dendrobium nobile* Lindl.), Huang-Qin (*Scutellaria baicalensis* Georgi), Sheng-Di-Huang (*Rehmannia glutinosa* Libosch.), Tian-Men-Dong (*Asparagus cochinchinensis* (Lour.)Merr.)\                                                                                                                                                                                                                                                                                                                                   1,552                     31    3                        0.09 (0.03-0.28)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}   0.10 (0.03-0.30)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}
                                      2.5:2.5:2.5:2.5:2.5:2.5:2.5:2.5:2.5:2.5:2.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

   Ma-Zi-Ren-Wan                      Huo-Ma-Ren (*Cannabis sativa* L.), Bai-Shao(*Paeonia sterniana* H.R.Fletcher), Zhi-Shi (*Citrus* × *aurantium* L.), Da-Hunag (*Rheum officinale* Baill.), Hou-Po (*Magnolia officinalis* Rehder & E.H. Wilson), Xing-Ren (*Prunus armeniaca* L.)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1,439                     22    3                        0.15 (0.05-0.47)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}   0.15 (0.05-0.48)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}
                                      7.5:2.5:2.5:5.0:2.5:2.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

   Ji-Sheng-Shen-Qi-Wan               Shou-Di-Huang (*Rehmannia glutinosa* Libosch.), Shan-Zhu-Yu (*Cornus officinalis* Siebold & Zucc.), Shan-Yao (*Dioscorea opposita* Thunb.), Fu-Ling (Poria cocos (Schw.) Wolff), Mu-Dan-Pi (*Paeonia* × *suffruticosa* Andrews), Ze-Xie (*Alisma orientale* (Sam.) Juz.), Fu-Zi (*Aconitum carmichaelii* Debeaux), Rou-Gui (*Cinnamomun cassia* Presl), Niu-Xi (*Achyranthes bidentata* Blume), Che-Qian-Zi (*Plantago asiatica* L.)\                                                                                                                                                                                                                                                                                                                                                                                                                           1,364                     24    7                        0.29 (0.13-0.62)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}   0.28 (0.13-0.60)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}
                                      8:4:4:6:3:3:1:1:2:2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

   Tian-Wang-Bu-Xin-Dan               Tian-Men-Dong (*Asparagus cochinchinensis* (Lour.) Merr.), Ren-Shen (*Panax ginseng* C.A.Mey.), Fu-Ling (*Poria cocos* (Schw.) Wolff), Xuan-Shen (*Scrophularia ningpoensis* Hemsl.), Dan-Shen (*Salvia miltiorrhiza* Bunge), Yuan-Zhi (*Polygala tenuifolia* Willd.), Jie-Geng (*Platycodon grandifloras* (Jacq.) A.DC.), Dang-Gui (*Angelica sinensis* (Oliv.) Diels), Wu-Wei-Zi (*Schisandra chinensis* (Turcz.) Baill.), Mai-Dong (*Ophiopogon japonicus* (Thunb.) Ker-Gawl.), Bai-Zi-Ren (*Platycladus orientalis* (L.) Franco), Suan-Zao-Ren (*Ziziphus jujuba* Mill. var. spinosa (Bunge) Hu ex H. F. Chou), Sheng-Di-Huang (*Rehmannia glutinosa* Libosch.)\                                                                                                                                                                                            1,338                     22    7                        0.31 (0.14-0.66)[\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}     0.28 (0.13-0.61)[\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}
                                      2:1:1:1:1:1:1:2:2:2:2:2:8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

   Shao-Yao-Gan-Cao-Tang              Bai-Shao(*Paeonia sterniana* H.R.Fletcher), Zhi-Gan-Cao (*Glycyrrhiza glabra* L.)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              1,298                     37    12                       0.29 (0.16-0.52)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}   0.30 (0.16-0.56)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}
                                      12:12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

   Zhi-Bai-Di-Huang-Wan               Shou-Di-Huang (*Rehmannia glutinosa* Libosch.), Shan-Zhu-Yu (*Cornus officinalis* Siebold & Zucc.), Fu-Ling (*Poria cocos* (Schw.) Wolff), Shan-Yao (*Dioscorea opposita* Thunb.), Mu-Dan-Pi (*Paeonia* × *suffruticosa* Andrews), Ze-Xie (*Alisma orientale* (Sam.) Juz.), Zhi-Mu (*Anemarrhena asphodeloides* Bge.), Huang-Bai (*Phellodendron chinense* Schneid.)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           1,052                     28    9                        0.28 (0.14-0.56)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}   0.29 (0.15-0.59)[\*\*\*](#table-fn16-1534735420943280){ref-type="table-fn"}
                                      8:4:3:4:3:3:2:2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: HR, hazard ratio; CHM, Chinese herbal medicine; MM, multiple myeloma.

Relative HR.

Represented adjusted HR: mutually adjusted for CHM use, age, gender, urbanization level, and Charlson Comorbidity Index score in Cox proportional hazard regression.

*P* \< .05. \*\**P* \< .01. \*\*\**P* \< .001.

To understand the safety of CHM, we compared the incidences of chronic kidney disease (CKD) and chronic hepatitis in our cohorts. During the follow-up period, the incidence of CKD has no significant difference in the CHM group and non-CHM group (6.09 vs 6.42 per 100 person-years, 95% CI = 0.46-1.95); the incidence of chronic hepatitis has no significant difference in the CHM group and non-CHM group (10.81 vs 4.42 per 1,000 person-years, 95% CI = 0.27-21.86). Additionally, the cumulative incidences of CKD and chronic hepatitis, as calculated by the Kaplan--Meier method, revealed no significant difference between the CHM cohort and the non-CHM cohort in patients with MM (*P* value = .969 and .324, respectively).

Discussion {#section13-1534735420943280}
==========

A large-scale, long-term follow-up, comprehensive database such as the NHIRD in Taiwan is helpful in decreasing participation bias and selection bias because of its large sample size.^[@bibr15-1534735420943280]^ The basic characteristics of the enrolled patients with MM in this study were compatible with those observed in clinical practice, such as the use of bortezomib and HSCT, and were variable factors in this study.^[@bibr20-1534735420943280]^ We noted similar characteristics between the 2 cohorts after 1:1 propensity score matching. To the best of our knowledge, this is the first study to reveal the benefit of the risk control of survival resulting from CHM treatment in individuals with MM. The survival rate from targeted therapies such as bortezomib may not convince patients, leading them to seek integrative therapies for better outcomes.^[@bibr21-1534735420943280]^ Currently, clinical doctors are greatly interested in CHM treatment for MM because of its popularity as an integrative therapy in Taiwan.^[@bibr22-1534735420943280]^ The therapeutic results of CHM in MM patients had previously been reported in the form of quality of life.^[@bibr23-1534735420943280]^ However, whether MM patients have a higher survival rate after CHM therapy has never been explored. Our results showed that the benefit of CHM intervention was independent of sex, age, comorbidities, and standard Western medical treatment, such as bortezomib or HSCT.

The incidence of MM throughout the world is very different, although age and genetic environmental and occupational factors have been associated with the pathogenesis of MM. Caucasian populations from the United States and Europe have a higher incidence of MM than individuals of Chinese descent in China and Singapore.^[@bibr24-1534735420943280][@bibr25-1534735420943280]-[@bibr26-1534735420943280]^ However, the incidence of MM has shown an increasing trend in the past decades throughout the world. There are no definitive reasons for this phenomenon.^[@bibr27-1534735420943280][@bibr28-1534735420943280][@bibr29-1534735420943280]-[@bibr30-1534735420943280]^ The incidence per 10,000 individuals of MM is 0.75 among Taiwanese adults and 5.2 in Taiwanese elderly individuals.^[@bibr31-1534735420943280]^ Approximately 50% of MM patients respond to traditional chemotherapy, but most elderly individuals cannot tolerate it.^[@bibr32-1534735420943280]^ Taiwanese patients still seek to improve the treatment effect and minimize the severity of complications from chemotherapy or targeted therapy through integrative interventions, and CHM is always their first choice.

Our results demonstrated that CHM treatment was associated with better survival rates in MM patients. Compared with the non-CHM group, the CHM group had a lower adjusted HR of 0.68 (95% CI = 0.24-0.51). Furthermore, patients with longer CHM treatment courses tended to have better survival status. The dose-dependence relationship showed the possibility of an effect of CHM in MM treatment. The association between the lag time to treatment and outcome is a well-discussed topic among leukemia patients. Analysis regarding the median lag time to treatment for subgroups stratified by treatment duration is presented in [Table 3](#table3-1534735420943280){ref-type="table"}. Although patients with the longest treatment duration had the shortest medical lag time, those who had treatment duration of 60 to 179 days presented with the longest medical lag time. This result may not support the role of lag time as a significant factor in the outcome of the treatment. HSCT has been suggested to MM patients for long-term control. Prior to the analysis, the percentage of patients with HSCT in the 2 cohorts was almost identical. This suggests that whether patients accepted HSCT did not change the final result of CHM intervention.

The Kaplan-Meier curves stratified by age are presented in [Figure 3](#fig3-1534735420943280){ref-type="fig"}. The correlation between age and survival rate can be noted, which matches the clinical situation in the real world. In each of the age subgroups, we can find that CHM truly improves the survival rate. Currently, the treatment of elderly MM patient remains a great challenge because they are unable to submit to full-dose chemotherapy due to their physical characteristics.^[@bibr33-1534735420943280]^ In other words, if the benefit of survival improvement did not come from CHM, we would have noted as such in [Figure 4](#fig4-1534735420943280){ref-type="fig"}.

Herbal safety is an important topic for clinical doctors and patients taking CHM. We investigated the incidences of developing CKD and chronic hepatitis in CHM and non-CHM groups during follow-up period. The results showed no significant difference between these 2 groups, which represent that CHM treatment is a safe intervention or, at least, does no harm to MM patients.

Chinese herbal medicine has been investigated with regard to its effect in controlling complications from chemotherapy or radiation therapy in cancer patients. Some clinical human trials have also shown that CHM is of benefit for the treatment of cancer.^[@bibr34-1534735420943280]^ However, there is little evidence of the benefit of CHM in treating individuals with malignant hematologic diseases. Therefore, we disclosed the top 10 single and combinations of herbal products used to treat MM in Taiwan in the hope that they will be further candidates for a potential treatment choice.

Conclusions {#section14-1534735420943280}
===========

Our study shows that CHM treatment was beneficial for MM patients. Although it is difficult to determine whether this phenomenon could be attributed to CHM alone, a synergistic effect or to an unrelated relieving of complications, this study nevertheless provides important ideas for more comprehensive investigations in the future.
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